Skip to main content

Table 2 Bleeding characteristics of the study subjects

From: Hemostatic efficacy and safety of the hemostatic powder UI-EWD in patients with lower gastrointestinal bleeding

Variables

Conventional therapy (n = 112)

UI-EWD therapy (n = 55)

P-value

Location of bleeding, n (%)

Cecum

5 (4.5)

2 (3.6)

0.625

Ascending colon

18 (16.1)

5 (9.1)

0.219

Hepatic flexure

0 (0.0)

4 (7.3)

0.011+

Transverse colon

12 (10.7)

4 (7.3)

0.478

Descending colon

5 (4.5)

1 (1.8)

0.388

Sigmoid colon

13 (11.6)

10 (18.2)

0.247

Rectum

59 (52.7)

29 (52.7)

0.830

Cause of bleeding, n (%)

Diverticular bleeding

13 (11.6)

4 (7.3)

0.204

Radiation proctitis

13 (11.6)

1 (1.8)

0.037+

Angiodysplasia

9 (8.0)

1 (1.8)

0.168+

Ulcer bleeding

34 (30.4)

18 (32.7)

0.756

Post procedure bleeding

31 (27.7)

25 (45.5)

0.147+

Tumor bleeding

12 (10.7)

6 (10.9)

0.970

Size of bleeding site, n (%)

 < 1 cm

71 (63.4)

15 (27.3)

 < 0.001

1–4 cm

32 (28.6)

26 (47.3)

0.022

 > 4 cm

9 (8.0)

14 (25.5)

0.002

Forrest classification, n (%)

Ia

2 (1.8)

5 (9.1)

0.040+

Ib

112 (94.6)

50 (90.1)

0.001+

Treatment modality, n (%)

Coagrasper

38 (33.0)

22 (40.0)

0.397

APC

21 (18.8)

5 (9.1)

0.106

Hemoclipping

81 (53.6)

21 (38.2)

 < 0.001

EVL

4 (3.6)

0 (0.0)

0.156

UI-EWD only

0 (0.0)

17 (30.9)

 
  1. +Fisher exact test
  2. *P-values were calculated using the t-test or Fisher calculated using the of the conventional therapy group and the UI-EWD therapy group